Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 56, Issue 3, pp 239–247 | Cite as

Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models

  • Christopher M. K. Springate
  • John K. Jackson
  • Martin E. Gleave
  • Helen M. BurtEmail author
Original Article

Abstract

Purpose

To develop and evaluate an injectable, controlled release delivery system for a phosphorothioate antisense oligonucleotide (ASO) based on complexed ASO:chitosan dispersed in a biodegradable polymeric paste for intratumoral treatment of solid tumors.

Methods

Clusterin ASO was complexed with chitosan particles and incorporated into a paste based on a 60:40 blend of methoxy-poly(ethylene glycol) (MePEG) and triblock copolymer of poly(D,L-lactic acid-co-caprolactone)-PEG-(D,L-lactic acid-co-caprolactone). In vitro release profiles of clusterin ASO into phosphate-buffered saline at 37°C were obtained under sink conditions and assayed by anionic exchange high-performance liquid chromatography. In vivo efficacy studies were carried out in human prostate PC-3 and LNCaP tumors grown subcutaneously in mice. Paste formulations of clusterin ASO with or without paclitaxel or docetaxel were injected intratumorally and tumor volumes and serum prostate specific antigen (PSA) levels were measured.

Results

Controlled release of clusterin ASO was obtained over several weeks. The rate and extent of ASO release was proportional to the ratio of ASO to chitosan in the paste. Treatment of mice bearing PC-3 tumors with clusterin ASO plus paclitaxel or docetaxel paste had reduced mean tumor volume by greater than 50% at 4 weeks. Treatment of mice bearing LNCaP tumors with clusterin ASO plus paclitaxel reduced mean tumor volume and serum PSA level by more than 50% and 70%, respectively.

Conclusions

Complexation of clusterin ASO with chitosan and incorporation into polymeric paste with paclitaxel or docetaxel produced in vitro controlled release of the ASO and in vivo efficacy over 4 weeks following a single intratumoral injection in solid human prostate tumors in mice.

Keywords

Chitosan Clusterin antisense oligonucleotide Paclitaxel Docetaxel Prostate cancer Complex 

Abbreviations

ASO

Phosphorothioate antisense oligonucleotide

CC

Chitosan complexes

CC paste

Formulations of an injectable polymeric paste loaded with chitosan complexes

MePEG

Methoxy-poly(ethylene glycol)

MMO

Mismatch oligonucleotide phosphorothioate

PEG

Poly(ethylene glycol)

PLC

Random poly(D,L-lactic acid-co-caprolactone) copolymer

PLC-PEG-PLC

Triblock copolymer of PLC and PEG in the form of PLC-PEG-PLC

PSA

Prostate specific antigen

Trizma

Tris(hydroxymethyl) aminomethane hydrochloride

Notes

Acknowledgements

This work was funded by research funding from ARC Pharmaceuticals Inc. to H.M. Burt and a grant from the Terry Fox Program Project of the National Cancer Institute of Canada to M.E. Gleave. A technology grant from the Science Council of British Columbia to ARC Pharmaceuticals Inc. is gratefully acknowledged. We thank Virginia Yago for her excellent technical assistance.

References

  1. 1.
    Veeramachaneni NK, Kubokura H, Lin L, Pippin JA, Patterson GA, Drebin JA, Battafarano RJ (2004) Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells. J Thorac Cardiovasc Surg 127:92–98PubMedGoogle Scholar
  2. 2.
    Pennati M, Binda M, Colella G, Zoppe M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N (2004) Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23:386–394PubMedGoogle Scholar
  3. 3.
    Caplen NJ, Mousses S (2003) Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann N Y Acad Sci 1002:56–62PubMedGoogle Scholar
  4. 4.
    Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, Sarris A, Lubenow N, Speiser D, Endres S, Hartmann G (2004) CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Immunobiology 103:2162–2169Google Scholar
  5. 5.
    Grate D, Wilson C (2001) Inducible regulation of the S. cerevisiae cell cycle mediated by an RNA aptamer-ligand complex. Bioorg Med Chem 9:2565–2570PubMedGoogle Scholar
  6. 6.
    Cho-Chung YS, Gewirtz AM, Stein CA (2003) Introduction. Ann N Y Acad Sci 1002:xi–xiiGoogle Scholar
  7. 7.
    Wang L, Prakash RK, Stein CA, Koehn RK, Ruffner DE (2003) Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Antisense Nucleic Acid Drug Dev 13:169–189PubMedGoogle Scholar
  8. 8.
    Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP, Gleave ME (2001) Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 298:934–940PubMedGoogle Scholar
  9. 9.
    Ferreiro MG, Tillman L, Hardee G, Bodmeier R (2001) Characterization of complexes of an antisense oligonucleotide with protamine and poly-L-lysine salts. J Control Release 73:381–390PubMedGoogle Scholar
  10. 10.
    Robaczewska M, Guerret S, Remy J-S, Chemin I, Offensperger W-B, Chevallier M, Behr J-P, Podhajska AJ, Blum HE, Trepo C, Cova L (2001) Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Ther 8:874–881PubMedGoogle Scholar
  11. 11.
    Ferreiro MG, Tillman LG, Hardee G, Bodmeier R (2002) Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides. Pharm Res 19:755–764PubMedGoogle Scholar
  12. 12.
    De Rosa G, Quaglia F, Bochot A, Ungaro F, Fattal E (2003) Long-term release and improved intracellular penetration of oligonucleotide-polyethylenimine complexes entrapped in biodegradable microspheres. Biomacromolecules 4:529–536PubMedGoogle Scholar
  13. 13.
    Mahato RI, Lee M, Han S, Maheshwari A, Kim SW (2001) Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol Ther 4:130–138PubMedGoogle Scholar
  14. 14.
    Jones SE, Jomary C (2002) Molecules in focus: clusterin. Int J Biochem Cell Biol 34:427–431PubMedGoogle Scholar
  15. 15.
    Gleave ME, Miyake H, Zellweger T, Chi K, July L, Nelson C, Rennie P (2001) Use of antisense oligonucleotides targeting the antiapoptotic gene clusterin/testosterone-repressed prostate message 2 to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology 58 [Suppl 2A]:39–49PubMedGoogle Scholar
  16. 16.
    Miyake H, Nelson C, Rennie PS, Gleave ME (2000) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60:170–176PubMedGoogle Scholar
  17. 17.
    Miyake H, Hara I, Kamidono S, Gleave M, Eto H (2003) Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol Rep 10:469–473PubMedGoogle Scholar
  18. 18.
    Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, Gleave ME (2003) Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int 92:463–469PubMedGoogle Scholar
  19. 19.
    July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME (2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50:179–188PubMedGoogle Scholar
  20. 20.
    Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES (2004) Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability and cell sensitization to genotoxic and oxidative stress. Cancer Res 64:1834–1842PubMedGoogle Scholar
  21. 21.
    Miyake H, Chi KN, Gleave ME (2000) Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6:1655–1663PubMedGoogle Scholar
  22. 22.
    Miyake H, Nelson C, Rennie PS, Gleave ME (2000) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 60:2547–2554PubMedGoogle Scholar
  23. 23.
    Crooke ST (2000) Evaluating the mechanism of action of antiproliferative antisense drugs. Antisense Nucleic Acid Drug Dev 10:123–126PubMedGoogle Scholar
  24. 24.
    Kuruma H, Fujita T, Shitara T, Egawa S, Yokoyama E, Baba S (2003) Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study. Int J Urol 10:470–475PubMedGoogle Scholar
  25. 25.
    Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA (2002) Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 94:1457–1465PubMedGoogle Scholar
  26. 26.
    Lapidus RG, Dang W, Rosen DM, Gady AM, Zabelinka Y, O’Meally R, DeWeese TL, Denmeade SR (2004) Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (Paclimer microspheres) and radiation. Prostate 58:291–298PubMedGoogle Scholar
  27. 27.
    Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM (2000) The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res 60:4146–4151PubMedGoogle Scholar
  28. 28.
    Jackson JK, Zhang X, Llewellen S, Hunter WL, Burt HM (2004) The characterization of novel polymeric paste formulations for intratumoral delivery. Int J Pharm 270:185–198PubMedGoogle Scholar
  29. 29.
    Lee KY, Ha WS, Park WH (1995) Blood compatibility and biodegradability of partially N-acylated chitosan derivatives. Biomaterials 16:1211–1216PubMedGoogle Scholar
  30. 30.
    Richardson SC, Kolbe HV, Duncan R (1999) Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm 178:231–243PubMedGoogle Scholar
  31. 31.
    Mi F-L, Tan Y-C, Liang H-F, Sung H-W (2002) In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant. Biomaterials 23:181–191PubMedGoogle Scholar
  32. 32.
    Venkatesh S, Smith TJ (1998) Chitosan-membrane interactions and their probable role in chitosan-mediated transfection. Biotechnol Appl Biochem 27(Pt 3):265–267PubMedGoogle Scholar
  33. 33.
    Park IK, Kim TH, Kim SI, Park YH, Kim WJ, Akaike T, Cho CS (2003) Visualization of transfection of hepatocytes by galactosylated chitosan-graft-poly(ethylene glycol)/DNA complexes by confocal laser scanning microscopy. Int J Pharm 257:103–110PubMedGoogle Scholar
  34. 34.
    MacLaughlin FC, Mumper RJ, Wang J, Tagliaferri JM, Gill I, Hinchcliffe M, Rolland AP (1998) Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release 56:259–272PubMedGoogle Scholar
  35. 35.
    Ishii T, Okahata Y, Sato T (2001) Mechanism of cell transfection with plasmid/chitosan complexes. Biochim Biophys Acta 1514:51–64PubMedGoogle Scholar
  36. 36.
    Chen J, Yang W-L, Qian J, Xue J-L, Fu S-K, Lu D-R (2003) Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J Gastroenterol 20:112–116Google Scholar
  37. 37.
    Erbacher P, Zou S, Bettinger T, Steffan A-M, Remy J-S (1998) Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res 15:1332–1339PubMedGoogle Scholar
  38. 38.
    Sato T, Ishii T, Okahata Y (2001) In vitro gene delivery mediated by chitosan. Effect of pH, serum, and molecular mass of chitosan on the transfection efficiency. Biomaterials 22:2075–2080PubMedGoogle Scholar
  39. 39.
    Mao HQ, Roy K, Troung L, Janes KA, Lin KY, Wang Y, August JT, Leong KW (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 70:399–421PubMedGoogle Scholar
  40. 40.
    Köping-Höggård M (2003) Relationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery system in vitro and in vivo. J Gene Med 5:130–141PubMedGoogle Scholar
  41. 41.
    Liggins RT, Burt HM (2001) Paclitaxel loaded poly(L-lactic acid) microspheres: properties of microspheres made with low molecular weight polymers. Int J Pharm 222:19–33PubMedGoogle Scholar
  42. 42.
    Winternitz CI, Jackson JK, Oktaba AM, Burt HM (1996) Development of a polymeric surgical paste formulation for taxol. Pharm Res 13:368–375PubMedGoogle Scholar
  43. 43.
    Papisov IM, Litmanovich AA (1998) Molecular “recognition” in interpolymer interactions and matrix polymerization. Adv Polym Sci 90:139–179Google Scholar
  44. 44.
    Hayatsu H, Kubo T, Tanaka Y, Negishi K (1997) Polynucleotide-chitosan complex an insoluble but reactive form of polynucleotide. Chem Pharm Bull 45:1363–1368PubMedGoogle Scholar
  45. 45.
    Vinogradov SV, Bronich TK, Kabanov AV (1998) Self-assembly of polyamine-poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjug Chem 9:805–812PubMedGoogle Scholar
  46. 46.
    Ho H-A, Boissinot M, Bergeron MG, Corbeil G, Doré K, Boudreau D, Leclerc M (2002) Colorimetric and fluorometric detection of nucleic acids using cationic polythiophene derivatives. Angew Chem Int Ed 41:1548–1551Google Scholar
  47. 47.
    Ojugo ASE, McSheehy PMJ, McIntyre DJO, McCoy C, Stubbs M, Leach MO, Judson IR, Griffiths JR (1999) Measurement of the extracellular pH of solid tumors in mice by magnetic resonance spectroscopy: a comparison of exogenous 19F and 31P probes. NMR Biomed 12:495–504PubMedGoogle Scholar
  48. 48.
    McSheehy PMJ, Troy H, Kelland LR, Judson IR, Leach MO, Griffiths JR (2003) Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. Eur J Pharm Sci 39:532–540Google Scholar
  49. 49.
    Raghunand N, Altbach MI, van Sluis R, Baggett B, Taylor CW, Bhujwalla ZM, Gillies RJ (1999) Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol 57:309–312PubMedGoogle Scholar
  50. 50.
    Sorlier P, Denuzière A, Viton C, Domard A (2001) Relation between the degree of acetylation and the electrostatic properties of chitin and chitosan. Biomacromolecules 2:765–772PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Christopher M. K. Springate
    • 1
    • 2
  • John K. Jackson
    • 2
  • Martin E. Gleave
    • 3
  • Helen M. Burt
    • 2
    Email author
  1. 1.ARC Pharmaceuticals IncVancouverCanada
  2. 2.Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical SciencesThe University of British ColumbiaVancouverCanada
  3. 3.The Prostate Centre, Vancouver General Hospital, Division of UrologyThe University of British ColumbiaVancouverCanada

Personalised recommendations